Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A SINGLE-DOSE, OPEN-LABEL, RANDOMIZED, 2-WAY CROSS-OVER, CLINICAL PHARMACOLOGY STUDY OF CHF 1535 35/4 NEXTHALER (DPI FIXED COMBINATION OF BECLOMETASONE DIPROPIONATE (BDP) 35 µg PLUS FORMOTEROL FUMARATE (FF) 4 µg VERSUS THE FREE COMBINATION OF LICENSED BDP DPI AND FF DPI IN ASTHMATIC CHILDREN

Next Previous
X
Search
Trial Profile

A SINGLE-DOSE, OPEN-LABEL, RANDOMIZED, 2-WAY CROSS-OVER, CLINICAL PHARMACOLOGY STUDY OF CHF 1535 35/4 NEXTHALER (DPI FIXED COMBINATION OF BECLOMETASONE DIPROPIONATE (BDP) 35 µg PLUS FORMOTEROL FUMARATE (FF) 4 µg VERSUS THE FREE COMBINATION OF LICENSED BDP DPI AND FF DPI IN ASTHMATIC CHILDREN

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Beclometasone/formoterol (Primary) ; Beclometasone; Formoterol
  • Indications Asthma
  • Focus Pharmacokinetics
  • Sponsors Chiesi Farmaceutici

    • Most Recent Events

    • 22 Jun 2017 Status changed from recruiting to completed.
    • 11 Apr 2017 Planned End Date changed from 1 Mar 2017 to 1 Jun 2017.
    • 11 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Jun 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top